Special Issue

Antibodies and Their Derivatives in Cancer Immunotherapy for Gastrointestinal Cancers

Message from the Guest Editors

Monoclonal antibodies, developed via hybridoma technology, a technology that also helped Georges Köhler, César Milstein, and Niels Jerne to win the Nobel prize in Physiology or Medicine in 1984, played a significant role in controlling several disease types. Applying the product of this Nobel prize-winning work in their revolutionary effort on the application of immune checkpoint blocker (ICB) monoclonal antibodies to improve the anticancer capabilities of T cells, in 2018, James P. Allison and Tasuku Honjo won the Nobel prize in Physiology or Medicine. Despite being successful in treating several cancer types, the success is very limited in gastrointestinal cancers, like in pancreatic cancer, where immune checkpoint blocking antibodies showed no such success. Similarly, for colorectal cancer, ICB treatment efficacy is limited for the microsatellite stable group. In most scenarios where ICB treatment works for a while, treatment resistance is another hurdle. We are pleased to invite you to contribute to this Special Issue to strengthen our understanding of the application of antibodies and their derivatives to improve cancer immunotherapy in this cancer group.

Guest Editors

Dr. Kiran Kundu

Department of Cancer Medicine, University of Oklahoma Stephenson Cancer Center, Oklahoma City, OK, USA

Dr. Susmita Ghosh

Department of Pathology, University of Oklahoma Stephenson Cancer Center, Oklahoma City, OK, USA

Deadline for manuscript submissions

24 July 2026

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/258943

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)